Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Costs and Expenses:
General and administrative	$ 6,474	$ 5,029
Research and development	7,800	5,131
Total Operating Costs and Expenses	14,274	10,160
Loss from Operations	(14,274)	(10,160)
Other Income :
Interest income	6	44
Total Other Income	6	44
Net Loss	(14,268)	(10,116)
Net Loss Attributable to Non-controlling Interest	(1)	(73)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(14,267)	(10,043)
Effect of Series A Preferred Stock Price adjustment	(7,402)	0
Effect of Warrant exercise price adjustment	0	(880)
Net Loss Attributable to Common Stockholders	$ (23,189)	$ (12,557)
Net Loss Per Share - Basic	$ (0.19)	$ (0.66)
Net Loss Per Share - Dilutive	$ (0.19)	$ (0.66)
Weighted average number of shares outstanding during the period - basic	121,875,042	19,011,362
Weighted average number of shares outstanding during the period - dilutive	121,875,042	19,011,362
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (24)	$ (254)
Effect of Series A Preferred Stock Price adjustment	(7,402)	0
Effect of Warrant exercise price adjustment		(1,000)
Series B Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	(1,496)	(1,380)
Preferred Stock [Member] | Series B Preferred Stock [Member]
Other Income :
Net Loss	$ 0	$ 0